Engineers Create First Immunocompetent Leukemia Device for CAR T Immunotherapy Screening

Engineers create first immunocompetent leukemia device for CAR T immunotherapy screening

A team of researchers led by NYU Tandon School of Engineering's Weiqiang Chen has developed a miniature device that could transform how blood cancer treatments are tested and tailored for patients.

"Leukemia-on-a-Chip” Developed to Evaluate CAR T-Cell Therapies

A team of researchers at NYU Tandon School of Engineering has created the first laboratory device that replicates both the structural and immune features of human bone marrow, allowing scientists to study how CAR T-cell immunotherapies interact with leukemia in real time. The microscope slide sized “leukemia on a chip” device uses patient-derived bone marrow cells that self-organize to produce their own cellular matrix, which could significantly…

NYU Tandon Engineers Create First Immunocompetent Leukemia Device for Car T Immunotherapy Screening

An NYU Tandon-led research team has developed a microscope slide-sized "leukemia-on-a-chip," the first laboratory device to successfully combine both the physical structure of bone marrow and a functioning human immune system, an advance that could dramatically accelerate new immunotherapy development.

NYU Tandon Engineers Develop First Immunocompetent Leukemia Model for

A breakthrough in cancer research has emerged from a team of engineers and biomedical scientists at NYU Tandon School of Engineering, led by Professor Weiqiang Chen. Their pioneering development of a microscope slide-sized "leukemia-on-a-chip" is poised to revolutionize the way blood cancer treatments are tested and personalized. This diminutive device replicates the complex bone marrow microenvironment and incorporates a functioning human immun…